

Gabelli Healthcare & WellnessRx Trust  
Form N-CSRS  
September 01, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM N-CSR**

**CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT**

**INVESTMENT COMPANIES**

Investment Company Act file number 811-22021

The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust  
(Exact name of registrant as specified in charter)

One Corporate Center

Rye, New York 10580-1422

(Address of principal executive offices) (Zip code)

Agnes Mullady

Gabelli Funds, LLC

One Corporate Center

Rye, New York 10580-1422

(Name and address of agent for service)

Registrant's telephone number, including area code: 1-800-422-3554

Date of fiscal year end: December 31

Date of reporting period: June 30, 2016

Form N-CSR is to be used by management investment companies to file reports with the Commission not later than 10 days after the transmission to stockholders of any report that is required to be transmitted to stockholders under Rule 30e-1 under the Investment Company Act of 1940 (17 CFR 270.30e-1). The Commission may use the information provided on Form N-CSR in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-CSR, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-CSR

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

unless the Form displays a currently valid Office of Management and Budget ( OMB ) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.

**Item 1. Reports to Stockholders.**

The Report to Shareholders is attached herewith.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Semiannual Report June 30, 2016****(Y)our Portfolio Management Team****Mario J. Gabelli, CFA Kevin V. Dreyer Jeff Jonas, CFA****To Our Shareholders,**

For the six months ended June 30, 2016, the net asset value ( NAV ) total return for The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust (the Fund ) was 5.9% compared with a total return of 0.4% for the Standard & Poor's ( S&P ) 500 Health Care Index. The total return for the Fund's publicly traded shares was 6.9%. The Fund's NAV per share was \$12.21, while the price of the publicly traded shares closed at \$10.68 on the New York Stock Exchange ( NYSE ). See below for additional performance information.

Enclosed are the financial statements, including the schedule of investments, as of June 30, 2016.

**Comparative Results****Average Annual Returns through June 30, 2016 (a) (Unaudited)**

|                                                                      | Year to Date | 1 Year | 3 Year | 5 Year | Since Inception (06/28/07) |
|----------------------------------------------------------------------|--------------|--------|--------|--------|----------------------------|
| <b>Gabelli Healthcare &amp; Wellness<sup>Rx</sup> Trust</b>          |              |        |        |        |                            |
| <b>NAV Total Return (b)</b>                                          | 5.87%        | 0.78%  | 13.85% | 15.83% | 11.17%                     |
| <b>Investment Total Return (c)</b>                                   | 6.91         | (0.10) | 11.27  | 15.82  | 8.96                       |
| S&P 500 Health Care Index                                            | 0.42         | (2.02) | 16.54  | 17.29  | 10.31                      |
| S&P 500 Index                                                        | 3.84         | 3.99   | 11.66  | 12.10  | 6.03                       |
| S&P 500 Consumer Staples Index                                       | 10.46        | 18.66  | 14.37  | 15.05  | 11.30                      |
| 50% S&P 500 Health Care Index and 50% S&P 500 Consumer Staples Index | 5.44         | 8.32   | 15.46  | 16.17  | 10.81                      |

(a) *Returns represent past performance and do not guarantee future results. Investment returns and the principal value of an investment will fluctuate. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit [www.gabelli.com](http://www.gabelli.com) for performance information as of the most recent month end. Performance returns for periods of less than one year are not annualized. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The S&P 500 Health Care Index is an unmanaged indicator of health care equipment and services, pharmaceuticals, biotechnology, and life sciences stock performance. The S&P 500 Index is an unmanaged indicator of stock market performance. The S&P 500 Consumer Staples Index is an unmanaged indicator of food and staples retailing, food, beverage and tobacco, and household and personal products stock performance. The Blended Index consists of a 50% blend of each of the S&P 500 Health Care Index and S&P 500 Consumer Staples Index. Dividends are considered reinvested. You cannot invest directly in an index.*

- (b) Total returns and average annual returns reflect changes in the NAV per share, reinvestment of distributions at NAV on the ex-dividend date, and adjustments for rights offerings and are net of expenses. Since inception return is based on an initial NAV of \$8.00.
- (c) Total returns and average annual returns reflect changes in closing market values on the NYSE, reinvestment of distributions, and adjustments for rights offerings. Since inception return is based on an initial offering price of \$8.00.

## Summary of Portfolio Holdings (Unaudited)

The following table presents portfolio holdings as a percent of total investments as of June 30, 2016:

### The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust

|                                    |        |
|------------------------------------|--------|
| Food                               | 20.5%  |
| Health Care Providers and Services | 18.5%  |
| Health Care Equipment and Supplies | 14.3%  |
| Pharmaceuticals                    | 12.4%  |
| Food and Staples Retailing         | 8.5%   |
| Beverages                          | 7.6%   |
| U.S. Government Obligations        | 6.0%   |
| Household and Personal Products    | 4.6%   |
| Biotechnology                      | 4.2%   |
| Electronics                        | 1.7%   |
| Specialty Chemicals                | 1.6%   |
| Hotels and Gaming                  | 0.1%   |
|                                    | 100.0% |

The Fund files a complete schedule of portfolio holdings with the Securities and Exchange Commission (the "SEC") for the first and third quarters of each fiscal year on Form N-Q. Shareholders may obtain this information at [www.gabelli.com](http://www.gabelli.com) or by calling the Fund at 800-GABELLI (800-422-3554). The Fund's Form N-Q is available on the SEC's website at [www.sec.gov](http://www.sec.gov) and may also be reviewed and copied at the SEC's Public Reference Room in Washington, DC. Information on the operation of the Public Reference Room may be obtained by calling 800-SEC-0330.

### Proxy Voting

The Fund files Form N-PX with its complete proxy voting record for the twelve months ended June 30, no later than August 31 of each year. A description of the Fund's proxy voting policies, procedures, and how the Fund voted proxies relating to portfolio securities is available without charge, upon request, by (i) calling 800-GABELLI (800-422-3554); (ii) writing to The Gabelli Funds at One Corporate Center, Rye, NY 10580-1422; or (iii) visiting the SEC's website at [www.sec.gov](http://www.sec.gov).

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Schedule of Investments June 30, 2016 (Unaudited)**

|                            |                                               |              |    | Market     |
|----------------------------|-----------------------------------------------|--------------|----|------------|
| Shares                     |                                               | Cost         |    | Value      |
| <b>COMMON STOCKS 94.0%</b> |                                               |              |    |            |
| <b>Beverages 7.6%</b>      |                                               |              |    |            |
| 35,000                     | Campbell Soup Co.                             | \$ 1,387,115 | \$ | 2,328,550  |
| 60,000                     | China Mengniu Dairy Co. Ltd.                  | 134,296      |    | 104,252    |
| 52,000                     | Danone SA                                     | 3,139,848    |    | 3,659,217  |
| 40,000                     | Dr Pepper Snapple Group Inc.                  | 1,161,404    |    | 3,865,200  |
| 26,000                     | ITO EN Ltd.                                   | 400,457      |    | 995,788    |
| 29,000                     | Massimo Zanetti Beverage Group SpA            | 354,756      |    | 236,222    |
| 10,000                     | Mead Johnson Nutrition Co.                    | 674,387      |    | 907,500    |
| 35,000                     | Morinaga Milk Industry Co. Ltd.               | 121,875      |    | 241,321    |
| 330,000                    | Parmalat SpA                                  | 900,527      |    | 857,685    |
| 30,000                     | PepsiCo Inc.                                  | 2,001,914    |    | 3,178,200  |
| 30,000                     | Suntory Beverage & Food Ltd.                  | 1,001,275    |    | 1,342,178  |
| 60,000                     | The Coca-Cola Co.                             | 1,730,696    |    | 2,719,800  |
| 50,000                     | The WhiteWave Foods Co.                       | 900,547      |    | 2,347,000  |
| 424,000                    | Vitasoy International Holdings Ltd.           | 253,570      |    | 769,508    |
|                            |                                               | 14,162,667   |    | 23,552,421 |
| <b>Biotechnology 4.2%</b>  |                                               |              |    |            |
| 8,500                      | Agilent Technologies Inc.                     | 345,376      |    | 377,060    |
| 1,000                      | Alexion Pharmaceuticals Inc.                  | 186,952      |    | 116,783    |
| 25,000                     | Amgen Inc.                                    | 2,350,738    |    | 3,803,750  |
| 62,690                     | BioTelemetry Inc.                             | 711,021      |    | 1,021,847  |
| 35,000                     | Charles River Laboratories International Inc. | 2,600,486    |    | 2,885,400  |
| 4,000                      | Illumina Inc.                                 | 212,969      |    | 561,520    |
| 75,000                     | Myriad Genetics Inc.                          | 2,487,806    |    | 2,295,000  |
| 160,000                    | NeoGenomics Inc.                              | 1,046,662    |    | 1,286,400  |
| 600                        | Regeneron Pharmaceuticals Inc.                | 229,467      |    | 209,538    |
| 20,000                     | Tetraphase Pharmaceuticals Inc.               | 149,868      |    | 86,000     |
| 1,600                      | Waters Corp.                                  | 197,843      |    | 225,040    |
|                            |                                               | 10,519,188   |    | 12,868,338 |
| <b>Electronics 1.7%</b>    |                                               |              |    |            |
| 35,000                     | Thermo Fisher Scientific Inc.                 | 4,206,605    |    | 5,171,600  |

| <b>Food 20.5%</b> |                              |           |           |
|-------------------|------------------------------|-----------|-----------|
| 15,000            | Calavo Growers Inc.          | 498,575   | 1,005,000 |
| 2,000             | Chr. Hansen Holding A/S      | 89,836    | 130,678   |
| 115,000           | ConAgra Foods Inc.           | 3,764,204 | 5,498,150 |
| 25,000            | Dean Foods Co.               | 349,560   | 452,250   |
| 67,500            | Flowers Foods Inc.           | 657,458   | 1,265,625 |
| 82,000            | General Mills Inc.           | 3,040,184 | 5,848,240 |
| 80,000            | Inventure Foods Inc.         | 362,437   | 624,800   |
| 5,400             | John B Sanfilippo & Son Inc. | 201,924   | 230,202   |
| 67,500            | Kellogg Co.                  | 3,770,078 | 5,511,375 |
| 35,000            | Kerry Group plc, Cl. A       | 1,331,659 | 3,110,032 |
| 150,000           | Kikkoman Corp.               | 1,768,541 | 5,447,151 |
| 73,000            | Lifeway Foods Inc.           | 757,998   | 705,910   |

**Market**

| <b>Shares</b> |                                       | <b>Cost</b> | <b>Value</b> |
|---------------|---------------------------------------|-------------|--------------|
| 23,000        | Maple Leaf Foods Inc.                 | \$ 410,536  | \$ 491,172   |
| 16,000        | MEIJI Holdings Co. Ltd.               | 334,973     | 1,616,036    |
| 120,000       | Mondelēz International Inc., Cl. A    | 3,244,616   | 5,461,200    |
| 53,000        | Nestlé SA                             | 2,945,832   | 4,078,802    |
| 10,000        | Pinnacle Foods Inc.                   | 428,315     | 462,900      |
| 50,000        | Post Holdings Inc.                    | 1,631,275   | 4,134,500    |
| 50,000        | Snyder s-Lance Inc.                   | 992,296     | 1,694,500    |
| 30,000        | The Kraft Heinz Co.                   | 1,884,620   | 2,654,400    |
| 12,000        | The Hain Celestial Group Inc.         | 128,931     | 597,000      |
| 27,000        | The J.M. Smucker Co.                  | 1,624,067   | 4,115,070    |
| 110,000       | Tingyi (Cayman Islands) Holding Corp. | 176,608     | 103,647      |
| 10,000        | TreeHouse Foods Inc.                  | 822,804     | 1,026,500    |
| 75,000        | Unilever plc, ADR                     | 2,456,358   | 3,593,250    |
| 65,000        | Yakult Honsha Co. Ltd.                | 1,908,326   | 3,323,488    |
|               |                                       | 35,582,011  | 63,181,878   |

| <b>Food and Staples Retailing 8.5%</b> |                               |            |            |
|----------------------------------------|-------------------------------|------------|------------|
| 30,000                                 | CST Brands Inc.               | 1,012,341  | 1,292,400  |
| 92,000                                 | CVS Health Corp.              | 4,078,478  | 8,808,080  |
| 30,000                                 | Ingles Markets Inc., Cl. A    | 454,430    | 1,119,000  |
| 225,000                                | Rite Aid Corp.                | 1,761,759  | 1,685,250  |
| 80,000                                 | The Kroger Co.                | 852,218    | 2,943,200  |
| 112,000                                | United Natural Foods Inc.     | 4,439,975  | 5,241,600  |
| 10,000                                 | Walgreens Boots Alliance Inc. | 626,338    | 832,700    |
| 134,000                                | Whole Foods Market Inc.       | 3,360,228  | 4,290,680  |
|                                        |                               | 16,585,767 | 26,212,910 |

| <b>Health Care Equipment and Supplies 14.3%</b> |                           |           |           |
|-------------------------------------------------|---------------------------|-----------|-----------|
| 57,829                                          | Baxter International Inc. | 2,182,644 | 2,615,027 |
| 28,001                                          | Becton, Dickinson and Co. | 3,979,593 | 4,748,637 |
| 45,000                                          | Boston Scientific Corp.   | 297,467   | 1,051,650 |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

|         |                              |           |           |
|---------|------------------------------|-----------|-----------|
| 35,000  | Cardiovascular Systems Inc.  | 452,957   | 643,125   |
| 71,672  | CareDx Inc.                  | 716,720   | 309,623   |
| 18,000  | Cutera Inc.                  | 138,709   | 201,780   |
| 30,311  | Exactech Inc.                | 588,507   | 810,516   |
| 45,000  | Gerresheimer AG              | 2,173,614 | 3,445,289 |
| 18,000  | Globus Medical Inc., Cl. A   | 440,449   | 428,940   |
| 25,000  | HeartWare International Inc. | 1,438,625 | 1,443,750 |
| 9,400   | Henry Schein Inc.            | 418,608   | 1,661,920 |
| 16,000  | ICU Medical Inc.             | 1,118,915 | 1,804,000 |
| 133,458 | InfuSystems Holdings Inc.    | 396,602   | 346,991   |
| 90,000  | Integer Holdings Corp.       | 3,103,632 | 2,783,700 |
| 125,000 | Lantheus Holdings Inc.       | 327,095   | 458,750   |
| 20,000  | Medtronic plc.               | 1,480,413 | 1,735,400 |
| 12,000  | NuVasive Inc.                | 438,738   | 716,640   |
| 0       | Nuvectra Corp.               | 3         | 3         |
| 46,574  | Orthofix International NV    | 1,396,266 | 1,974,738 |
| 13,000  | Patterson Companies Inc.     | 610,571   | 622,570   |
| 5,000   | Smith & Nephew plc, ADR      | 168,590   | 171,600   |
| 60,000  | Sparton Corp.                | 1,251,263 | 1,306,200 |
| 60,000  | St. Jude Medical Inc.        | 3,645,669 | 4,680,000 |
| 25,000  | Stryker Corp.                | 1,379,039 | 2,995,750 |

See accompanying notes to financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Schedule of Investments (Continued) June 30, 2016 (Unaudited)**

|                                                       |                                      | <b>Market</b> |              |
|-------------------------------------------------------|--------------------------------------|---------------|--------------|
| <b>Shares</b>                                         |                                      | <b>Cost</b>   | <b>Value</b> |
| <b>COMMON STOCKS (Continued)</b>                      |                                      |               |              |
| <b>Health Care Equipment and Supplies (Continued)</b> |                                      |               |              |
| 76,424                                                | SurModics Inc.                       | \$ 1,654,928  | \$ 1,794,436 |
| 20,000                                                | The Cooper Companies Inc.            | 2,073,197     | 3,431,400    |
| 15,900                                                | Zimmer Biomet Holdings Inc.          | 1,606,094     | 1,914,042    |
|                                                       |                                      | 33,478,908    | 44,096,477   |
| <b>Health Care Providers and Services 18.5%</b>       |                                      |               |              |
| 627,499                                               | AdCare Health Systems Inc.           | 2,233,697     | 1,154,598    |
| 50,209                                                | Adeptus Health Inc., Cl. A           | 2,586,660     | 2,593,797    |
| 152,500                                               | Alere Inc.                           | 5,196,856     | 6,356,200    |
| 25,000                                                | AmerisourceBergen Corp.              | 885,962       | 1,983,000    |
| 30,000                                                | Amsurg Corp.                         | 2,156,598     | 2,326,200    |
| 15,000                                                | Anthem Inc.                          | 1,739,000     | 1,970,100    |
| 21,698                                                | Chemed Corp.                         | 2,836,222     | 2,957,654    |
| 35,000                                                | Cigna Corp.                          | 1,850,097     | 4,479,650    |
| 55,000                                                | DaVita HealthCare Partners Inc.      | 3,146,020     | 4,252,600    |
| 75,000                                                | Diplomat Pharmacy Inc.               | 2,188,148     | 2,625,000    |
| 70,000                                                | HCA Holdings Inc.                    | 2,858,004     | 5,390,700    |
| 35,000                                                | Humana Inc.                          | 5,248,591     | 6,295,800    |
| 150,000                                               | Kindred Healthcare Inc.              | 1,775,439     | 1,693,500    |
| 26,000                                                | Laboratory Corp. of America Holdings | 2,963,674     | 3,387,072    |
| 15,000                                                | McKesson Corp.                       | 1,044,224     | 2,799,750    |
| 4,700                                                 | Rhoen Klinikum AG                    | 139,335       | 137,333      |
| 55,000                                                | Team Health Holdings Inc.            | 2,301,417     | 2,236,850    |
| 5,000                                                 | Tenet Healthcare Corp.               | 141,619       | 138,200      |
| 17,500                                                | UnitedHealth Group Inc.              | 1,853,832     | 2,471,000    |
| 25,000                                                | VCA Inc.                             | 1,337,300     | 1,690,250    |
|                                                       |                                      | 44,482,695    | 56,939,254   |
| <b>Hotels and Gaming 0.1%</b>                         |                                      |               |              |
| 9,021                                                 | Ryman Hospitality Properties Inc.    | 239,578       | 456,914      |
| <b>Household and Personal Products 4.6%</b>           |                                      |               |              |
| 16,000                                                | Avon Products Inc.                   | 120,268       | 60,480       |
| 22,000                                                | Church & Dwight Co. Inc.             | 1,374,290     | 2,263,580    |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

|        |                                        |            |            |
|--------|----------------------------------------|------------|------------|
| 30,000 | Colgate-Palmolive Co.                  | 1,859,734  | 2,196,000  |
| 50,000 | Coty Inc., Cl. A                       | 773,429    | 1,299,500  |
| 45,000 | Edgewell Personal Care Co.             | 3,785,810  | 3,798,450  |
| 30,000 | Energizer Holdings Inc.                | 982,875    | 1,544,700  |
| 25,000 | Sally Beauty Holdings Inc.             | 673,597    | 735,250    |
| 12,000 | The Estee Lauder Companies Inc., Cl. A | 804,724    | 1,092,240  |
| 13,000 | The Procter & Gamble Co.               | 1,000,591  | 1,100,710  |
|        |                                        | 11,375,318 | 14,090,910 |

**Pharmaceuticals 12.4%**

|           |                          |           |           |
|-----------|--------------------------|-----------|-----------|
| 30,000    | Abbott Laboratories      | 767,033   | 1,179,300 |
| 11,800    | Achaogen Inc.            | 113,674   | 44,722    |
| 120,000   | Akorn Inc.               | 3,435,377 | 3,418,200 |
| 27,201    | Allergan plc             | 4,319,998 | 6,285,875 |
| 1,100,000 | BioScrip Inc.            | 2,287,906 | 2,805,000 |
| 42,000    | Bristol-Myers Squibb Co. | 1,365,258 | 3,089,100 |

**Market**

| Shares |                                            | Cost       | Value      |
|--------|--------------------------------------------|------------|------------|
| 12,000 | Cempra Inc.                                | \$ 121,553 | \$ 197,880 |
| 9,000  | Endo International plc                     | 134,252    | 140,310    |
| 10,000 | Gilead Sciences Inc.                       | 980,200    | 834,200    |
| 44,000 | Johnson & Johnson                          | 3,504,264  | 5,337,200  |
| 55,000 | Juniper Pharmaceuticals Inc.               | 385,546    | 385,550    |
| 49,018 | Mallinckrodt plc                           | 3,078,749  | 2,979,314  |
| 50,000 | Merck & Co. Inc.                           | 1,719,422  | 2,880,500  |
| 30,000 | Mylan NV                                   | 1,498,203  | 1,297,200  |
| 1,000  | Ophthotech Corp.                           | 40,375     | 51,030     |
| 68,000 | Pfizer Inc.                                | 1,476,614  | 2,394,280  |
| 12,000 | Roche Holding AG, ADR                      | 250,094    | 395,400    |
| 4,001  | Shire plc, ADR                             | 773,011    | 736,483    |
| 40,000 | Teva Pharmaceutical Industries Ltd., ADR   | 2,440,792  | 2,009,200  |
| 15,000 | Valeant Pharmaceuticals International Inc. | 1,415,777  | 302,100    |
| 30,000 | Zoetis Inc.                                | 1,313,659  | 1,423,800  |
|        |                                            | 31,421,757 | 38,186,644 |

**Specialty Chemicals 1.6%**

|                            |                                         |             |             |
|----------------------------|-----------------------------------------|-------------|-------------|
| 38,000                     | International Flavors & Fragrances Inc. | 3,711,013   | 4,790,660   |
| <b>TOTAL COMMON STOCKS</b> |                                         | 205,765,507 | 289,548,006 |

**PREFERRED STOCKS 0.0%**

**Pharmaceuticals 0.0%**

|     |                            |        |       |
|-----|----------------------------|--------|-------|
| 146 | BioScrip Inc., Zero Coupon | 13,852 | 7,961 |
|-----|----------------------------|--------|-------|

**RIGHTS 0.0%**

**Health Care 0.0%**

|        |                              |   |     |
|--------|------------------------------|---|-----|
| 40,000 | American Medical Alert Corp. | 0 | 400 |
|--------|------------------------------|---|-----|

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

|                     |                               |   |        |
|---------------------|-------------------------------|---|--------|
| 40,000              | Durata Therapeutics Inc., CVR | 0 | 0      |
| 130,000             | Trius Therapeutics, CVR       | 0 | 16,900 |
| <b>TOTAL RIGHTS</b> |                               | 0 | 17,300 |

|                             |                                       |     |     |
|-----------------------------|---------------------------------------|-----|-----|
| <b>WARRANTS 0.0%</b>        |                                       |     |     |
| <b>Pharmaceuticals 0.0%</b> |                                       |     |     |
| 420                         | BioScrip Inc., Cl. A, expire 07/27/25 | 384 | 271 |
| 420                         | BioScrip Inc., Cl. B, expire 07/27/25 | 364 | 260 |
| <b>TOTAL WARRANTS</b>       |                                       | 748 | 531 |

**Principal  
Amount**

|                                         |                                                                    |               |             |
|-----------------------------------------|--------------------------------------------------------------------|---------------|-------------|
| <b>U.S. GOVERNMENT OBLIGATIONS 6.0%</b> |                                                                    |               |             |
| \$18,345,000                            | U.S. Treasury Bills,<br>0.220% to 0.481% ,<br>07/21/16 to 12/15/16 | 18,315,439    | 18,326,396  |
| <b>TOTAL INVESTMENTS 100.0%</b>         |                                                                    | \$224,095,546 | 307,900,194 |

See accompanying notes to financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Schedule of Investments (Continued) June 30, 2016 (Unaudited)**

|                                                 | <b>Market</b>       |
|-------------------------------------------------|---------------------|
|                                                 | <b>Value</b>        |
| <b>Other Assets and Liabilities (Net)</b>       | <b>\$ (248,568)</b> |
| <b>PREFERRED STOCK</b>                          |                     |
| (2,613,272 preferred shares outstanding)        | (65,331,800)        |
| <b>NET ASSETS COMMON STOCK</b>                  |                     |
| (19,848,104 common shares outstanding)          | \$ 242,319,826      |
| <b>NET ASSET VALUE PER COMMON SHARE</b>         |                     |
| (\$242,319,826 ÷ 19,848,104 shares outstanding) | \$ 12.21            |

|                                   | <b>% of Total</b>  | <b>Market</b>  |
|-----------------------------------|--------------------|----------------|
| <b>Geographic Diversification</b> | <b>Investments</b> | <b>Value</b>   |
| North America                     | 83.5%              | \$ 256,982,797 |
| Europe                            | 11.4               | 34,999,290     |
| Japan                             | 4.2                | 12,965,962     |
| Latin America                     | 0.7                | 2,182,637      |
| Asia/Pacific                      | 0.2                | 769,508        |
| Total Investments                 | 100.0%             | \$ 307,900,194 |

Non-income producing security.

Represents annualized yield at date of purchase.

ADR American Depositary Receipt

CVR Contingent Value Right

See accompanying notes to financial statements.

---

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**
**Statement of Assets and Liabilities****June 30, 2016 (Unaudited)****Assets:**

|                                            |                |
|--------------------------------------------|----------------|
| Investments, at value (cost \$224,095,546) | \$ 307,900,194 |
| Foreign currency, at value (cost \$1,356)  | 1,362          |
| Receivable for investments sold            | 1,562,583      |
| Receivable for Preferred Shares            | 60,763         |
| Dividends receivable                       | 398,326        |
| Deferred offering expense                  | 38,259         |
| Prepaid expenses                           | 3,663          |

|                     |                    |
|---------------------|--------------------|
| <b>Total Assets</b> | <b>309,965,150</b> |
|---------------------|--------------------|

**Liabilities:**

|                                      |           |
|--------------------------------------|-----------|
| Payable to custodian                 | 93,904    |
| Distributions payable                | 42,264    |
| Payable for investments purchased    | 1,750,220 |
| Payable for investment advisory fees | 248,800   |
| Payable for payroll expenses         | 46,725    |
| Payable for accounting fees          | 11,250    |
| Payable for legal and audit fees     | 39,891    |
| Other accrued expenses               | 80,470    |

|                          |                  |
|--------------------------|------------------|
| <b>Total Liabilities</b> | <b>2,313,524</b> |
|--------------------------|------------------|

**Preferred Shares:**

|                                                                                                                                                |            |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Series A Cumulative Preferred Shares (5.760%, \$25 liquidation value, \$0.001 par value, 1,200,000 shares authorized, issued, and outstanding) | 30,000,000 |
| Series B Cumulative Preferred Shares (5.875%, \$25 liquidation value, \$0.001 par value, 1,413,272 shares authorized, issued, and outstanding) | 35,331,800 |

|                               |                   |
|-------------------------------|-------------------|
| <b>Total Preferred Shares</b> | <b>65,331,800</b> |
|-------------------------------|-------------------|

|                                                       |                       |
|-------------------------------------------------------|-----------------------|
| <b>Net Assets Attributable to Common Shareholders</b> | <b>\$ 242,319,826</b> |
|-------------------------------------------------------|-----------------------|

**Net Assets Attributable to Common Shareholders Consist of:**

|                                                                                |                |
|--------------------------------------------------------------------------------|----------------|
| Paid-in capital                                                                | \$ 156,360,477 |
| Accumulated net investment loss                                                | (76,941)       |
| Accumulated net realized gain on investments and foreign currency transactions | 2,238,093      |
| Net unrealized appreciation on investments                                     | 83,804,648     |

|                                                              |         |
|--------------------------------------------------------------|---------|
| Net unrealized depreciation on foreign currency translations | (6,451) |
|--------------------------------------------------------------|---------|

|                   |                       |
|-------------------|-----------------------|
| <b>Net Assets</b> | <b>\$ 242,319,826</b> |
|-------------------|-----------------------|

**Net Asset Value per Common Share:**

|                                                                                                             |         |
|-------------------------------------------------------------------------------------------------------------|---------|
| (\$242,319,826 ÷ 19,848,104 shares outstanding at \$0.001 par value; unlimited number of shares authorized) | \$12.21 |
|-------------------------------------------------------------------------------------------------------------|---------|

**Statement of Operations****For the Six Months Ended June 30, 2016 (Unaudited)****Investment Income:**

|                                                          |              |
|----------------------------------------------------------|--------------|
| Dividends (net of foreign withholding taxes of \$70,017) | \$ 1,720,529 |
| Interest                                                 | 85,663       |

|                                |                  |
|--------------------------------|------------------|
| <b>Total Investment Income</b> | <b>1,806,192</b> |
|--------------------------------|------------------|

**Expenses:**

|                                     |           |
|-------------------------------------|-----------|
| Investment advisory fees            | 1,463,311 |
| Shareholder communications expenses | 101,428   |
| Payroll expenses                    | 83,641    |
| Shareholder services fees           | 50,396    |
| Legal and audit fees                | 40,220    |
| Trustees fees                       | 29,588    |
| Accounting fees                     | 22,500    |
| Custodian fees                      | 12,304    |
| Shelf registration expense          | 5,463     |
| Miscellaneous expenses              | 33,981    |

|                       |                  |
|-----------------------|------------------|
| <b>Total Expenses</b> | <b>1,842,832</b> |
|-----------------------|------------------|

**Less:**

|                                                 |         |
|-------------------------------------------------|---------|
| Expenses paid indirectly by broker (See Note 3) | (1,597) |
| Custodian fee credits                           | (149)   |

|                                     |                |
|-------------------------------------|----------------|
| <b>Total Reductions and Credits</b> | <b>(1,746)</b> |
|-------------------------------------|----------------|

|                     |                  |
|---------------------|------------------|
| <b>Net Expenses</b> | <b>1,841,086</b> |
|---------------------|------------------|

|                            |                 |
|----------------------------|-----------------|
| <b>Net Investment Loss</b> | <b>(34,894)</b> |
|----------------------------|-----------------|

**Net Realized and Unrealized Gain on Investments and Foreign Currency:**

|                                                    |            |
|----------------------------------------------------|------------|
| Net realized gain on investments                   | 10,386,212 |
| Net realized gain on foreign currency transactions | 2,419      |

|                                                                    |            |
|--------------------------------------------------------------------|------------|
| Net realized gain on investments and foreign currency transactions | 10,388,631 |
|--------------------------------------------------------------------|------------|

|                                                                                                      |                      |
|------------------------------------------------------------------------------------------------------|----------------------|
| Net change in unrealized appreciation/depreciation:                                                  |                      |
| on investments                                                                                       | 4,898,777            |
| on foreign currency translations                                                                     | 2,700                |
| Net change in unrealized appreciation/ depreciation on investments and foreign currency translations | 4,901,477            |
| <b>Net Realized and Unrealized Gain on Investments and Foreign Currency</b>                          | <b>15,290,108</b>    |
| <b>Net Increase in Net Assets Resulting from Operations</b>                                          | <b>15,255,214</b>    |
| Total Distributions to Preferred Shareholders                                                        | (1,895,301)          |
| <b>Net Increase in Net Assets Attributable to Common Shareholders Resulting from Operations</b>      | <b>\$ 13,359,913</b> |

See accompanying notes to financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Statement of Changes in Net Assets Attributable To Common Shareholders**

|                                                                                                     | <b>Six Months Ended<br/>June 30, 2016<br/>(Unaudited)</b> | <b>Year Ended<br/>December 31, 2015</b> |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------|
| <b>Operations:</b>                                                                                  |                                                           |                                         |
| Net investment loss                                                                                 | \$ (34,894)                                               | \$ (548,868)                            |
| Net realized gain on investments, securities sold short, and foreign currency transactions          | 10,388,631                                                | 13,541,361                              |
| Net change in unrealized appreciation/depreciation on investments and foreign currency translations | 4,901,477                                                 | 1,452,983                               |
| <b>Net Increase in Net Assets Resulting from Operations</b>                                         | <b>15,255,214</b>                                         | <b>14,445,476</b>                       |
| <b>Distributions to Preferred Shareholders:</b>                                                     |                                                           |                                         |
| Net realized short term gain                                                                        |                                                           | (755,611)                               |
| Net realized long term gain                                                                         | (1,895,301)*                                              | (3,007,615)                             |
| <b>Total Distributions to Preferred Shareholders</b>                                                | <b>(1,895,301)</b>                                        | <b>(3,763,226)</b>                      |
| <b>Net Increase in Net Assets Attributable to Common Shareholders Resulting from Operations</b>     | <b>13,359,913</b>                                         | <b>10,682,250</b>                       |
| <b>Distributions to Common Shareholders:</b>                                                        |                                                           |                                         |
| Net realized short term gain                                                                        |                                                           | (2,033,000)                             |
| Net realized long term gain                                                                         | (5,160,507)*                                              | (8,092,097)                             |
| <b>Total Distributions to Common Shareholders</b>                                                   | <b>(5,160,507)</b>                                        | <b>(10,125,097)</b>                     |
| <b>Fund Share Transactions:</b>                                                                     |                                                           |                                         |
| Net decrease from repurchase of common shares                                                       |                                                           | (1,040,516)                             |
| Offering costs for common shares charged to paid-in capital                                         |                                                           | (14,724)                                |
| Net increase in net assets from offering of preferred shares                                        | 23,027                                                    |                                         |
| <b>Net Increase/(Decrease) in Net Assets from Fund Share Transactions</b>                           | <b>23,027</b>                                             | <b>(1,055,240)</b>                      |
| <b>Net Increase/(Decrease) in Net Assets Attributable to Common Shareholders</b>                    | <b>8,222,433</b>                                          | <b>(498,087)</b>                        |
| <b>Net Assets Attributable to Common Shareholders:</b>                                              |                                                           |                                         |
| Beginning of year                                                                                   | 234,097,393                                               | 234,595,480                             |

|                                                                                            |                |                |
|--------------------------------------------------------------------------------------------|----------------|----------------|
| End of period (including undistributed net investment income of \$0 and \$0, respectively) | \$ 242,319,826 | \$ 234,097,393 |
|--------------------------------------------------------------------------------------------|----------------|----------------|

\* Based on year to date book income. Amounts are subject to change and recharacterization at year end.  
See accompanying notes to financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Financial Highlights**

**Selected data for a common share of beneficial interest outstanding throughout each period:**

|                                                                                                             | <b>Six Months Ended<br/>June 30,<br/>2016<br/>(Unaudited)</b> | <b>2015</b> | <b>Year Ended December 31,</b> |             |             |         |
|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------|--------------------------------|-------------|-------------|---------|
|                                                                                                             |                                                               | <b>2014</b> | <b>2013</b>                    | <b>2012</b> | <b>2011</b> |         |
| <b>Operating Performance:</b>                                                                               |                                                               |             |                                |             |             |         |
| Net asset value, beginning of year                                                                          | \$11.79                                                       | \$11.76     | \$11.33                        | \$ 9.55     | \$ 8.51     | \$ 8.47 |
| Net investment income/(loss)                                                                                | (0.00)(a)                                                     | (0.03)      | 0.01                           | 0.04        | 0.05        | 0.01    |
| Net realized and unrealized gain<br>on investments, and foreign<br>currency transactions                    | 0.78                                                          | 0.75        | 2.04                           | 3.53        | 2.25        | 0.95    |
| Total from investment operations                                                                            | 0.78                                                          | 0.72        | 2.05                           | 3.57        | 2.30        | 0.96    |
| <b>Distributions to Preferred Shareholders: (b)</b>                                                         |                                                               |             |                                |             |             |         |
| Net investment income                                                                                       |                                                               |             |                                | (0.01)      | (0.00)(a)   |         |
| Net realized short term/long term<br>gain                                                                   | (0.10)*                                                       | (0.19)      | (0.13)                         | (0.12)      | (0.15)      | (0.16)  |
| Total distributions to preferred<br>shareholders                                                            | (0.10)                                                        | (0.19)      | (0.13)                         | (0.13)      | (0.15)      | (0.16)  |
| <b>Net Increase in Net Assets<br/>Attributable to Common<br/>Shareholders Resulting from<br/>Operations</b> |                                                               |             |                                |             |             |         |
|                                                                                                             | 0.68                                                          | 0.53        | 1.92                           | 3.44        | 2.15        | 0.80    |
| <b>Distributions to Common Shareholders:</b>                                                                |                                                               |             |                                |             |             |         |
| Net investment income                                                                                       |                                                               |             |                                | (0.01)      | (0.05)      |         |
| Net realized short term/long term<br>gain                                                                   | (0.26)*                                                       | (0.51)      | (0.62)                         | (0.90)      | (1.04)      |         |
| Return of capital                                                                                           |                                                               |             |                                |             | (0.02)      |         |
| Total distributions to common<br>shareholders                                                               | (0.26)                                                        | (0.51)      | (0.62)                         | (0.91)      | (1.11)      |         |

**Fund Share Transactions:**

|                                                                          |           |        |        |           |           |        |
|--------------------------------------------------------------------------|-----------|--------|--------|-----------|-----------|--------|
| Increase in net asset value for repurchase of common share               | 0.01      |        |        |           |           |        |
| Decrease in net asset value from common shares issued in rights offering |           | (0.77) | (0.72) |           | (0.72)    |        |
| Offering costs for preferred shares charged to paid-in capital           |           | (0.08) |        |           |           |        |
| Recapture of gain on sale of Fund shares by an affiliate                 |           |        |        |           |           | (0.00) |
| Offering costs for common shares charged to paid-in capital              | (0.00)(a) | (0.02) | (0.03) | (0.00)(a) | (0.04)    |        |
| Increase in net asset value from offering of preferred shares            | 0.00(a)   |        |        |           |           |        |
| Total Fund share transactions                                            | 0.00      | 0.01   | (0.87) | (0.75)    | (0.00)(a) | (0.76) |

**Net Asset Value Attributable to Common Shareholders, End of Period**

|                             |         |         |         |         |         |         |
|-----------------------------|---------|---------|---------|---------|---------|---------|
|                             | \$12.21 | \$11.79 | \$11.76 | \$11.33 | \$ 9.55 | \$ 8.51 |
| NAV total return            | 5.87%   | 4.55%   | 16.98%  | 36.86%  | 25.37%  | 8.80%   |
| Market value, end of period | \$10.68 | \$10.25 | \$10.42 | \$10.38 | \$ 8.62 | \$ 7.14 |
| Investment total return     | 6.91%   | 3.14%   | 10.39%  | 35.99%  | 36.33%  | 6.68%   |

See accompanying notes to financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Financial Highlights (Continued)**

Selected data for a common share of beneficial interest outstanding throughout each period:

|                                                                                                                                | Six Months Ended<br>June 30,<br>2016<br>(Unaudited) | 2015      | 2014      | 2013      | 2012      | 2011      |
|--------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-----------|-----------|-----------|-----------|-----------|
| <b>Ratios to Average Net Assets and Supplemental Data:</b>                                                                     |                                                     |           |           |           |           |           |
| Net assets including liquidation value of preferred shares, end of period (in 000 s)                                           | \$307,652                                           | \$299,097 | \$299,595 | \$199,503 | \$137,181 | \$125,576 |
| Net assets attributable to common shares, end of period (in 000 s)                                                             | \$242,320                                           | \$234,097 | \$234,595 | \$169,503 | \$107,181 | \$ 95,576 |
| Ratio of net investment income/(loss) to average net assets attributable to common shares before preferred share distributions | (0.03)%(c)                                          | (0.22)%   | (0.27)%   | 0.02%     | 0.56%     | (0.44)%   |
| Ratio of operating expenses to average net assets attributable to common shares                                                | 1.61%(c)(d)                                         | 1.60%(e)  | 1.63%     | 1.71%     | 1.94%     | 2.22%     |
| Ratio of operating expenses to average net assets including liquidation value of preferred shares                              | 1.26%(c)(e)                                         | 1.26%(e)  | 1.36%     | 1.41%     | 1.52%     | 1.66%     |
| Portfolio turnover rate                                                                                                        | 20.0%(c)                                            | 52.4%     | 43.5%     | 52.1%     | 46.6%     | 66.2%     |
| <b>Preferred Shares:</b>                                                                                                       |                                                     |           |           |           |           |           |
| <b>5.760% Series A Cumulative Preferred Shares</b>                                                                             |                                                     |           |           |           |           |           |
| Liquidation value, end of period (in                                                                                           | \$ 30,000                                           | \$ 30,000 | \$ 30,000 | \$ 30,000 | \$ 30,000 | \$ 30,000 |

000 s)

|                                                    |             |             |             |             |             |             |
|----------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Total shares outstanding (in 000 s)                | 1,200       | 1,200       | 1,200       | 1,200       | 1,200       | 1,200       |
| Liquidation preference per share                   | \$ 25.00    | \$ 25.00    | \$ 25.00    | \$ 25.00    | \$ 25.00    | \$ 25.00    |
| Average market value (f)                           | \$ 26.14    | \$ 25.96    | \$ 25.85    | \$ 26.47    | \$ 27.46    | \$ 26.34    |
| Asset coverage per share (g)                       | \$ 117.73   | \$ 115.04   | \$ 115.23   | \$ 166.25   | \$ 114.32   | \$ 104.65   |
| <b>5.875% Series B Cumulative Preferred Shares</b> |             |             |             |             |             |             |
| Liquidation value, end of period (in 000 s)        | \$ 35,332   | \$ 35,000   | \$ 35,000   |             |             |             |
| Total shares outstanding (in 000 s)                | 1,413       | 1,400       | 1,400       |             |             |             |
| Liquidation preference per share                   | \$ 25.00    | \$ 25.00    | \$ 25.00    |             |             |             |
| Average market value (f)                           | \$ 27.04    | \$ 26.09    | \$ 25.37    |             |             |             |
| Asset coverage per share (g)                       | \$ 117.73   | \$ 115.04   | \$ 115.23   |             |             |             |
| <b>Asset Coverage (h)</b>                          | <b>471%</b> | <b>460%</b> | <b>461%</b> | <b>665%</b> | <b>457%</b> | <b>419%</b> |

Based on net asset value per share at commencement of operations of \$8.00 per share, adjusted for reinvestment of distributions at the net asset value per share on ex-dividend dates including the effect of shares issued pursuant to the rights offerings, assuming full subscription by shareholders. Total return for a period of less than one year is not annualized.

Based on market value per share at initial public offering of \$8.00 per share, adjusted for reinvestment of distributions at prices determined under the Fund's dividend reinvestment plan including the effect of shares issued pursuant to the rights offerings, assuming full subscription by shareholders.

\* Based on year to date book income. Amounts are subject to change and recharacterization at year end.

(a) Amount represents less than \$0.005 per share.

(b) Calculated based upon average common shares outstanding on the record dates throughout the periods.

(c) Annualized.

(d) The Fund received credits from a designated broker who agreed to pay certain Fund operating expenses. In the six months ended June 30, 2016, there was no impact on this expense ratio.

(e) The Fund received credits from a designated broker who agreed to pay certain Fund operating expenses. Had such payments not been made, this expense ratio for the year ended December 31, 2015 would have been 1.27%. For the six months ended June 30, 2016, there was no impact.

(f) Based on weekly prices.

(g) Asset coverage per share is calculated by combining all series of preferred shares.

(h) Asset coverage is calculated by combining all series of preferred shares.

See accompanying notes to financial statements.

## The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust

### Notes to Financial Statements (Unaudited)

**1. Organization.** The Gabelli Healthcare & WellnessRx Trust (the Fund ) currently operates as a diversified closed-end management investment company organized as a Delaware statutory trust on February 20, 2007 and registered under the Investment Company Act of 1940 as amended (the 1940 Act ). Investment operations commenced on June 28, 2007.

The Fund's investment objective is long term growth of capital. The Fund will invest at least 80% of its assets, under normal market conditions, in equity securities and income producing securities of domestic and foreign companies in the healthcare and wellness industries. As a result, the Fund may be more susceptible to economic, political, and regulatory developments in this particular sector of the market, positive or negative, and may experience increased volatility to the Fund's NAV and a magnified effect in its total return.

**2. Significant Accounting Policies.** As an investment company, the Fund follows the investment company accounting and reporting guidance, which is part of U.S. generally accepted accounting principles ( GAAP ) that may require the use of management estimates and assumptions in the preparation of its financial statements. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements.

**Security Valuation.** Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market's official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the Board ) so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC (the Adviser ).

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market, but prior to the close of business on the day the securities are being valued. Debt instruments with remaining maturities of sixty days or less that are not credit impaired are valued at amortized cost, unless the Board determines such amount does not reflect the securities' fair value, in which case these securities will be fair valued as determined by the Board. Debt instruments having a maturity greater than sixty days for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price. U.S. government obligations with maturities greater than sixty days are normally valued using a model that incorporates market observable data such as reported sales of similar securities, broker quotes, yields, bids, offers, and reference data. Certain securities are valued principally using dealer quotations. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board. Fair valuation methodologies and procedures may include, but are not limited to: analysis and review of available

financial and non-financial information about the company; comparisons with the valuation and

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Notes to Financial Statements (Unaudited) (Continued)**

changes in valuation of similar securities, including a comparison of foreign securities with the equivalent U.S. dollar value American Depositary Receipts securities at the close of the U.S. exchange; and evaluation of any other information that could be indicative of the value of the security.

The inputs and valuation techniques used to measure fair value of the Fund's investments are summarized into three levels as described in the hierarchy below:

Level 1 quoted prices in active markets for identical securities;

Level 2 other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and

Level 3 significant unobservable inputs (including the Board's determinations as to the fair value of investments).

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input both individually and in the aggregate that is significant to the fair value measurement. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of the Fund's investments in securities by inputs used to value the Fund's investments as of June 30, 2016 is as follows:

|                                        | Valuation Inputs         |                                                |                                            | Total Market Value<br>at 6/30/16 |
|----------------------------------------|--------------------------|------------------------------------------------|--------------------------------------------|----------------------------------|
|                                        | Level 1<br>Quoted Prices | Level 2 Other Significant<br>Observable Inputs | Level 3 Significant<br>Unobservable Inputs |                                  |
| INVESTMENTS IN SECURITIES:             |                          |                                                |                                            |                                  |
| ASSETS (Market Value):                 |                          |                                                |                                            |                                  |
| Common Stocks(a)                       | \$289,548,006            |                                                |                                            | \$289,548,006                    |
| Preferred Stocks(a)                    |                          | \$ 7,961                                       |                                            | 7,961                            |
| Rights(a)                              |                          |                                                | \$17,300                                   | 17,300                           |
| Warrants(a)                            |                          | 531                                            |                                            | 531                              |
| U.S. Government Obligations            |                          | 18,326,396                                     |                                            | 18,326,396                       |
|                                        |                          |                                                |                                            |                                  |
| TOTAL INVESTMENTS IN SECURITIES ASSETS | \$289,548,006            | \$18,334,888                                   | \$17,300                                   | \$307,900,194                    |

(a) Please refer to the Schedule of Investments for the industry classifications of these portfolio holdings. The Fund did not have transfers among Level 1, Level 2, and Level 3 during the six months ended June 30, 2016. The Fund's policy is to recognize transfers among Levels as of the beginning of the reporting period.

**Additional Information to Evaluate Qualitative Information.**

**General.** The Fund uses recognized industry pricing services approved by the Board and unaffiliated with the Adviser to value most of its securities, and uses broker quotes provided by market makers of securities not valued by these and other recognized pricing sources. Several different pricing feeds are received to value domestic equity securities, international equity securities, preferred equity securities, and fixed income securities. The data within these feeds is ultimately sourced from major stock exchanges and trading systems where these securities trade. The prices supplied by external sources are checked by obtaining quotations or actual transaction prices from market participants. If a price obtained from the pricing source is deemed unreliable, prices will be sought from another pricing service or from a broker/dealer that trades that security or similar securities.

**Fair Valuation.** Fair valued securities may be common and preferred equities, warrants, options, rights, and fixed income obligations. Where appropriate, Level 3 securities are those for which market quotations are

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Notes to Financial Statements (Unaudited) (Continued)**

not available, such as securities not traded for several days, or for which current bids are not available, or which are restricted as to transfer. Among the factors to be considered to fair value a security are recent prices of comparable securities that are publicly traded, reliable prices of securities not publicly traded, the use of valuation models, current analyst reports, valuing the income or cash flow of the issuer, or cost if the preceding factors do not apply. A significant change in the unobservable inputs could result in a lower or higher value in Level 3 securities. The circumstances of Level 3 securities are frequently monitored to determine if fair valuation measures continue to apply.

The Adviser reports quarterly to the Board the results of the application of fair valuation policies and procedures. These may include back testing the prices realized in subsequent trades of these fair valued securities to fair values previously recognized.

***Derivative Financial Instruments.*** The Fund may engage in various portfolio investment strategies by investing in a number of derivative financial instruments for the purposes of increasing the income of the Fund, hedging against changes in the value of its portfolio securities and in the value of securities it intends to purchase, or hedging against a specific transaction with respect to either the currency in which the transaction is denominated or another currency. Investing in certain derivative financial instruments, including participation in the options, futures, or swap markets, entails certain execution, liquidity, hedging, tax, and securities, interest, credit, or currency market risks. Losses may arise if the Adviser's prediction of movements in the direction of the securities, foreign currency, and interest rate markets is inaccurate. Losses may also arise if the counterparty does not perform its duties under a contract, or that, in the event of default, the Fund may be delayed in or prevented from obtaining payments or other contractual remedies owed to it under derivative contracts. The creditworthiness of the counterparties is closely monitored in order to minimize these risks. Participation in derivative transactions involves investment risks, transaction costs, and potential losses to which the Fund would not be subject absent the use of these strategies. The consequences of these risks, transaction costs, and losses may have a negative impact on the Fund's ability to pay distributions.

***Forward Foreign Exchange Contracts.*** The Fund may engage in forward foreign exchange contracts for the purpose of hedging a specific transaction with respect to either the currency in which the transaction is denominated or another currency as deemed appropriate by the Adviser. Forward foreign exchange contracts are valued at the forward rate and are marked-to-market daily. The change in market value is included in unrealized appreciation/depreciation on investments and foreign currency translations. When the contract is closed, the Fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed.

The use of forward foreign exchange contracts does not eliminate fluctuations in the underlying prices of the Fund's portfolio securities, but it does establish a rate of exchange that can be achieved in the future. Although forward foreign exchange contracts limit the risk of loss due to a decline in the value of the hedged currency, they also limit any potential gain that might result should the value of the currency increase. During the six months ended June 30, 2016, the Fund held no investments in forward foreign exchange contracts.

***Limitations on the Purchase and Sale of Futures Contracts, Certain Options, and Swaps.*** Subject to the guidelines of the Board, the Fund may engage in commodity interest transactions (generally, transactions in futures, certain options, certain currency transactions, and certain types of swaps) only for bona fide hedging or other permissible

transactions in accordance with the rules and regulations of the Commodity Futures Trading

---

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Notes to Financial Statements (Unaudited) (Continued)**

Commission ( CFTC ). Pursuant to amendments by the CFTC to Rule 4.5 under the Commodity Exchange Act ( CEA ), the Adviser has filed a notice of exemption from registration as a commodity pool operator with respect to the Fund. The Fund and the Adviser are therefore not subject to registration or regulation as a commodity pool operator under the CEA. In addition, certain trading restrictions are now applicable to the Fund as of January 1, 2013. These trading restrictions permit the Fund to engage in commodity interest transactions that include (i) bona fide hedging transactions, as that term is defined and interpreted by the CFTC and its staff, without regard to the percentage of the Fund's assets committed to margin and options premiums and (ii) non-bona fide hedging transactions, provided that the Fund does not enter into such non-bona fide hedging transactions if, immediately thereafter, either (a) the sum of the amount of initial margin deposits on the Fund's existing futures positions or swaps positions and option or swaption premiums would exceed 5% of the market value of the Fund's liquidating value, after taking into account unrealized profits and unrealized losses on any such transactions, or (b) the aggregate net notional value of the Fund's commodity interest transactions would not exceed 100% of the market value of the Fund's liquidating value, after taking into account unrealized profits and unrealized losses on any such transactions. Therefore, in order to claim the Rule 4.5 exemption, the Fund is limited in its ability to invest in commodity futures, options, and certain types of swaps (including securities futures, broad based stock index futures, and financial futures contracts). As a result, in the future, the Fund will be more limited in its ability to use these instruments than in the past, and these limitations may have a negative impact on the ability of the Adviser to manage the Fund, and on the Fund's performance.

**Securities Sold Short.** The Fund may enter into short sale transactions. Short selling involves selling securities that may or may not be owned and, at times, borrowing the same securities for delivery to the purchaser, with an obligation to replace such borrowed securities at a later date. The proceeds received from short sales are recorded as liabilities and the Fund records an unrealized gain or loss to the extent of the difference between the proceeds received and the value of an open short position on the day of determination. The Fund records a realized gain or loss when the short position is closed out. By entering into a short sale, the Fund bears the market risk of an unfavorable change in the price of the security sold short. Dividends on short sales are recorded as an expense by the Fund on the ex-dividend date and interest expense is recorded on the accrual basis. The broker retains collateral for the value of the open positions, which is adjusted periodically as the value of the position fluctuates. At June 30, 2016, there were no short sales outstanding.

**Foreign Currency Translations.** The books and records of the Fund are maintained in U.S. dollars. Foreign currencies, investments, and other assets and liabilities are translated into U.S. dollars at current exchange rates. Purchases and sales of investment securities, income, and expenses are translated at the exchange rate prevailing on the respective dates of such transactions. Unrealized gains and losses that result from changes in foreign exchange rates and/or changes in market prices of securities have been included in unrealized appreciation/depreciation on investments and foreign currency translations. Net realized foreign currency gains and losses resulting from changes in exchange rates include foreign currency gains and losses between trade date and settlement date on investment securities transactions, foreign currency transactions, and the difference between the amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial purchase trade date and subsequent sale trade date is included in realized gain/(loss) on investments.



**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Notes to Financial Statements (Unaudited) (Continued)**

**Foreign Securities.** The Fund may directly purchase securities of foreign issuers. Investing in securities of foreign issuers involves special risks not typically associated with investing in securities of U.S. issuers. The risks include possible revaluation of currencies, the inability to repatriate funds, less complete financial information about companies, and possible future adverse political and economic developments. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than securities of comparable U.S. issuers.

**Foreign Taxes.** The Fund may be subject to foreign taxes on income, gains on investments, or currency repatriation, a portion of which may be recoverable. The Fund will accrue such taxes and recoveries as applicable, based upon its current interpretation of tax rules and regulations that exist in the markets in which it invests.

**Restricted Securities.** The Fund may invest without limit in restricted securities. Restricted securities include securities whose disposition is subject to substantial legal or contractual restrictions. The sale of restricted securities often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted securities may sell at a price lower than similar securities that are not subject to restrictions on resale. Securities freely saleable among qualified institutional investors under special rules adopted by the SEC may be treated as liquid if they satisfy liquidity standards established by the Board. The continued liquidity of such securities is not as well assured as that of publicly traded securities, and accordingly the Board will monitor their liquidity. The Fund held no restricted securities at June 30, 2016.

**Securities Transactions and Investment Income.** Securities transactions are accounted for on the trade date with realized gain/(loss) on investments determined by using the identified cost method. Interest income (including amortization of premium and accretion of discount) is recorded on the accrual basis. Premiums and discounts on debt securities are amortized using the effective yield to maturity method. Dividend income is recorded on the ex-dividend date, except for certain dividends from foreign securities that are recorded as soon after the ex-dividend date as the Fund becomes aware of such dividends.

**Custodian Fee Credits and Interest Expense.** When cash balances are maintained in the custody account, the Fund receives credits which are used to offset custodian fees. The gross expenses paid under the custody arrangement are included in custodian fees in the Statement of Operations with the corresponding expense offset, if any, shown as Custodian fee credits. When cash balances are overdrawn, the Fund is charged an overdraft fee equal to 110% of the 90 day Treasury Bill rate on outstanding balances. This amount, if any, would be included in the Statement of Operations.

**Distributions to Shareholders.** Distributions to common shareholders are recorded on the ex-dividend date. Distributions to shareholders are based on income and capital gains as determined in accordance with federal income tax regulations, which may differ from income and capital gains as determined under GAAP. These differences are primarily due to differing treatments of income and gains on various investment securities and foreign currency transactions held by the Fund, timing differences, and differing characterizations of distributions made by the Fund. Distributions from net investment income for federal income tax purposes include net realized gains on foreign currency transactions. These book/tax differences are either temporary or permanent in nature. To the extent these differences are permanent, adjustments are made to the appropriate capital accounts in the period when the differences

arise. These reclassifications have no impact on the NAV of the Fund.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Notes to Financial Statements (Unaudited) (Continued)**

Distributions to shareholders of the Fund's 5.76% Series A Cumulative Preferred Shares (Series A Preferred) and 5.875% Series B Cumulative Preferred Shares (Series B Preferred) are recorded on a daily basis and are determined as described in Note 5.

The tax character of distributions paid during the year ended December 31, 2015 was as follows:

|                                                         | <b>Common</b>     | <b>Preferred</b> |
|---------------------------------------------------------|-------------------|------------------|
| <b>Distributions paid from:</b>                         |                   |                  |
| Ordinary income (inclusive of short term capital gains) | \$ 2,033,000      | \$ 755,611       |
| Net long term capital gains                             | 8,092,097         | 3,007,615        |
| <br>Total distributions paid                            | <br>\$ 10,125,097 | <br>\$ 3,763,226 |

**Provision for Income Taxes.** The Fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended (the Code). It is the policy of the Fund to comply with the requirements of the Code applicable to regulated investment companies and to distribute substantially all of its net investment company taxable income and net capital gains. Therefore, no provision for federal income taxes is required.

As of December 31, 2015, the components of accumulated earnings/losses on a tax basis were as follows:

|                                                                              |                   |
|------------------------------------------------------------------------------|-------------------|
| Undistributed long term capital gains                                        | \$ 85,984         |
| Net unrealized appreciation on investments and foreign currency translations | 77,716,006        |
| Other temporary differences*                                                 | (42,047)          |
| <br>Total                                                                    | <br>\$ 77,759,943 |

\* Other temporary differences are primarily due to adjustments on preferred share class distribution payables. The Fund is permitted to carry capital losses forward for an unlimited period. Capital losses that are carried forward will retain their character as either short term or long term capital losses.

The following summarizes the tax cost of investments and the related net unrealized appreciation at June 30, 2016:

**Cost**

|                    |                      | <b>Gross<br/>Unrealized<br/>Appreciation</b> | <b>Gross<br/>Unrealized<br/>Depreciation</b> | <b>Net Unrealized<br/>Appreciation</b> |
|--------------------|----------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|
| <b>Investments</b> | <b>\$225,324,450</b> | <b>\$90,148,208</b>                          | <b>\$(7,572,464)</b>                         | <b>\$82,575,744</b>                    |

The Fund is required to evaluate tax positions taken or expected to be taken in the course of preparing the Fund's tax returns to determine whether the tax positions are more-likely-than-not of being sustained by the applicable tax authority. Income tax and related interest and penalties would be recognized by the Fund as tax expense in the Statement of Operations if the tax positions were deemed not to meet the more-likely-than-not threshold. For the six months ended June 30, 2016, the Fund did not incur any income tax, interest, or penalties. As of June 30, 2016, the Adviser has reviewed all open tax years and concluded that there was no impact to the Fund's net assets or results of operations. The Fund's federal and state tax returns for the prior three fiscal years remain open, subject to examination. On an ongoing basis, the Adviser will monitor the Fund's tax positions to determine if adjustments to this conclusion are necessary.

**3. Agreements and Transactions with Affiliates.** The Fund has entered into an investment advisory agreement (the Advisory Agreement) with the Adviser which provides that the Fund will pay the Adviser a fee, computed weekly and paid monthly, equal on an annual basis to 1.00% of the value of the Fund's average weekly net assets including the liquidation value of preferred shares. In accordance with the Advisory Agreement, the

## The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust

### Notes to Financial Statements (Unaudited) (Continued)

Adviser provides a continuous investment program for the Fund's portfolio and oversees the administration of all aspects of the Fund's business and affairs.

During the six months ended June 30, 2016, the Fund paid brokerage commissions on security trades of \$7,836 to G.research, LLC, an affiliate of the Adviser.

During the six months ended June 30, 2016, the Fund received credits from a designated broker who agreed to pay certain Fund operating expenses. The amount of such expenses paid through this directed brokerage arrangement during this period was \$1,597.

The cost of calculating the Fund's NAV per share is a Fund expense pursuant to the Advisory Agreement. During the six months ended June 30, 2016, the Fund paid or accrued \$22,500 to the Adviser in connection with the cost of computing the Fund's NAV.

As per the approval of the Board, the Fund compensates officers of the Fund, who are employed by the Fund and are not employed by the Adviser (although the officers may receive incentive based variable compensation from affiliates of the Adviser). For the six months ended June 30, 2016, the Fund accrued \$83,641 in payroll expenses in the Statement of Operations.

The Fund pays each Trustee who is not considered an affiliated person an annual retainer of \$3,000 plus \$1,000 for each Board meeting attended. Each Trustee is reimbursed by the Fund for any out of pocket expenses incurred in attending meetings. All Board committee members receive \$500 per meeting attended. In addition, the Audit Committee Chairman receives an annual fee of \$3,000, the Nominating Committee Chairman receives an annual fee of \$2,000, and the Lead Trustee receives an annual fee of \$1,000. A Trustee may receive a single meeting fee, allocated among the participating funds, for participation in certain meetings held on behalf of multiple funds. Trustees who are directors or employees of the Adviser or an affiliated company receive no compensation or expense reimbursement from the Fund.

**4. Portfolio Securities.** Purchases and sales of securities during the six months ended June 30, 2016, other than short term securities and U.S. Government obligations, aggregated \$54,996,719 and \$54,920,470, respectively.

**5. Capital.** The Fund is authorized to issue an unlimited number of shares of beneficial interest (par value \$0.001). The Board has authorized the repurchase of its shares on the open market when the shares are trading on the NYSE at a discount of 10% or more (or such other percentage as the Board may determine from time to time) from the NAV of the shares. During the year ended December 31, 2015, the Fund repurchased and retired 94,048 shares in the open market at a cost of \$1,040,516 and an average discount of approximately 11.53% from its NAV. There were no common shares repurchased during the six months ended June 30, 2016.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Notes to Financial Statements (Unaudited) (Continued)**

Transactions in common stock were as follows:

|                                                                     | <b>Six Months Ended</b> |               |                          |                       |
|---------------------------------------------------------------------|-------------------------|---------------|--------------------------|-----------------------|
|                                                                     | <b>June 30, 2016</b>    |               | <b>Year Ended</b>        |                       |
|                                                                     | <b>(Unaudited)</b>      |               | <b>December 31, 2015</b> |                       |
|                                                                     | <b>Shares</b>           | <b>Amount</b> | <b>Shares</b>            | <b>Amount</b>         |
| Increase in net assets from common shares issued in rights offering |                         |               |                          |                       |
| Net decrease from repurchase of common shares                       |                         |               | (94,048)                 | \$ (1,040,516)        |
| <b>Total</b>                                                        |                         |               | <b>(94,048)</b>          | <b>\$ (1,040,516)</b> |

The Fund filed a \$200 million shelf registration statement that became effective April 29, 2016, enabling the Fund to offer additional common and preferred shares.

On June 17, 2013, the Fund distributed one transferable right for each of the 11,217,460 common shares outstanding on that date. Three rights were required to purchase one additional common share at the subscription price of \$9.00 per share. On July 25, 2013, the Fund issued 3,739,154 common shares receiving proceeds of \$33,279,402, after the deduction of offering expenses of \$372,984. The NAV per share of the Fund was reduced by approximately \$0.75 per share as a result of the issuance of shares below NAV.

On June 3, 2014, the Fund distributed one transferable right for each of the 14,956,614 common shares outstanding on that date. Three rights were required to purchase one additional common share at the subscription price of \$9.00 per share authorized by the Board in accordance with the offering document. On July 16, 2014, the Fund issued 4,985,538 common shares receiving net proceeds of \$44,533,886, after the deduction of offering expenses of \$335,956. The NAV per share of the Fund was reduced by approximately \$0.77 per share on the day the additional shares were issued. The additional shares were issued below NAV.

The Fund's Declaration of Trust, as amended, authorizes the issuance of an unlimited number of shares of \$0.001 par value Preferred Shares. The Preferred Shares are senior to the common shares and result in the financial leveraging of the common shares. Such leveraging tends to magnify both the risks and opportunities to common shareholders. Dividends on Preferred Shares are cumulative. The Fund is required by the 1940 Act and by the Statement of Preferences to meet certain asset coverage tests with respect to the Preferred Shares. If the Fund fails to meet these requirements and does not correct such failure, the Fund may be required to redeem, in part or in full, the Preferred Shares at redemption prices of \$25 per share plus an amount equal to the accumulated and unpaid dividends whether or not declared on such shares in order to meet these requirements. Additionally, failure to meet the foregoing asset coverage requirements could restrict the Fund's ability to pay dividends to common shareholders and could lead to sales of portfolio securities at inopportune times. The income received on the Fund's assets may vary in a manner

unrelated to the fixed rates, which could have either a beneficial or detrimental impact on net investment income and gains available to common shareholders.

On August 20, 2010, the Fund received net proceeds of \$28,725,173 (after underwriting discounts of \$945,000 and offering expenses of \$329,827) from the public offering of 1,200,000 shares of Series A Preferred. The Fund, at its option, may redeem the Series A Preferred in whole or in part at the redemption price per share plus an amount equal to the accumulated and unpaid dividends whether or not declared on such shares. The Board has authorized the repurchase of the Series A Preferred in the open market at prices less than the \$25 liquidation value per share. During the six months ended June 30, 2016, the Fund did not repurchase any of

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust****Notes to Financial Statements (Unaudited) (Continued)**

the Series A Preferred. At June 30, 2016, 1,200,000 Series A Preferred were outstanding and accrued dividends amounted to \$19,200.

On September 24, 2014, the Fund received net proceeds of \$33,564,647 (after underwriting discounts of \$1,102,500 and offering expenses of \$332,853) from the public offering of 1,400,000 shares of Series B Preferred. Commencing September 24, 2019 and at any time thereafter, the Fund, at its option, may redeem the Series B Preferred in whole or in part at the redemption price per share plus an amount equal to the accumulated and unpaid dividends whether or not declared on such shares. The Board has authorized the repurchase of the Series B Preferred in the open market at prices less than the \$25 liquidation value per share. During the period ended June 30, 2016, the Fund did not repurchase any of the Series B Preferred. At June 30, 2016, 1,413,272 Series B Preferred were outstanding and accrued dividends amounted to \$23,064.

The following table summarizes the data relating to the at the market offering of the Fund's Series B Preferred:

| <b>Year</b> | <b>Shares Issued</b> | <b>Net Proceeds</b> | <b>Sales Manager Commissions</b> | <b>Net Proceeds in Excess of Par</b> |
|-------------|----------------------|---------------------|----------------------------------|--------------------------------------|
| 2016        | 13,272               | \$354,827           | \$892                            | \$23,027                             |

As of June 30, 2016, after considering the issuance of the of the preferred B shares, the Fund has approximately \$119,774,439 available for issuance under the current shelf offering.

The following table summarizes the Preferred Share information:

| <b>Series</b> | <b>Issue Date</b>  | <b>Number of Shares Issued/Authorized</b> | <b>Number of Shares Outstanding at 06/30/16</b> | <b>Net Proceeds</b> | <b>2016 Dividend Rate Range</b> | <b>Dividend Rate at 06/30/16</b> | <b>Accrued Dividend at 06/30/16</b> |
|---------------|--------------------|-------------------------------------------|-------------------------------------------------|---------------------|---------------------------------|----------------------------------|-------------------------------------|
| A 5.760%      | August 20, 2010    | 1,200,000                                 | 1,200,000                                       | \$28,725,173        | Fixed Rate                      | 5.760%                           | \$19,200                            |
| B 5.875%      | September 24, 2014 | 1,413,272                                 | 1,413,272                                       | 33,919,474          | Fixed Rate                      | 5.875%                           | 23,064                              |

The holders of Preferred Shares generally are entitled to one vote per share held on each matter submitted to a vote of shareholders of the Fund and will vote together with holders of common stock as a single class. The holders of Preferred Shares voting together as a single class also have the right currently to elect two Trustees and under certain circumstances are entitled to elect a majority of the Board. In addition, the affirmative vote of a majority of the votes entitled to be cast by holders of all outstanding shares of the Preferred Shares, voting as a single class, will be required to approve any plan of reorganization adversely affecting the Preferred Shares, and the approval of two-thirds of each class, voting separately, of the Fund's outstanding voting stock must approve the conversion of the Fund from a

closed-end to an open-end investment company. The approval of a majority (as defined in the 1940 Act) of the outstanding Preferred Shares and a majority (as defined in the 1940 Act) of the Fund's outstanding voting securities are required to approve certain other actions, including changes in the Fund's investment objectives or fundamental investment policies.

**6. Industry Concentration.** Because the Fund primarily invests in common stocks and other securities of foreign and domestic companies in the health care, pharmaceuticals, and food and beverage industries, its portfolio may be subject to greater risk and market fluctuations than a portfolio of securities representing a broad range of investments.

**7. Indemnifications.** The Fund enters into contracts that contain a variety of indemnifications. The Fund's maximum exposure under these arrangements is unknown. However, the Fund has not had prior claims or

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Notes to Financial Statements (Unaudited) (Continued)**

losses pursuant to these contracts. Management has reviewed the Fund's existing contracts and expects the risk of loss to be remote.

**8. Subsequent Events.** Management has evaluated the impact of all subsequent events of the Fund and has determined that there were no subsequent events requiring recognition or disclosure in the financial statements.

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Notes to Financial Statements (Unaudited) (Continued)**

**Shareholder Meeting May 9, 2016 Final Results**

The Fund's Annual Meeting of Shareholders was held on May 9, 2016 at the Greenwich Library in Greenwich, Connecticut. At that meeting, common and preferred shareholders, voting together as a single class, elected Jeffrey J. Jonas, CFA, and Kuni Nakamura as Trustees of the Fund. A total of 18,100,911 votes, and 18,086,168 votes were cast in favor of these Trustees, and a total of 1,551,378 votes, and 1,566,122 votes were withheld for these Trustees, respectively. In addition, preferred shareholders, voting as a separate class, elected James P. Conn as a Trustee of the Fund. A total of 1,946,534 votes were cast in favor of this Trustee and a total of 51,984 votes were withheld for this Trustee.

Mario J. Gabelli, CFA, Anthony J. Colavita, Vincent D. Enright, Robert C. Kolodny, MD, Anthonie C. van Ekris, and Salvatore J. Zizza continue to serve in their capacities as Trustees of the Fund.

We thank you for your participation and appreciate your continued support.

## **The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

### **Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited)**

Section 15(c) of the Investment Company Act of 1940, as amended (the 1940 Act ), contemplates that the Board of Trustees (the Board ) of The Gabelli Healthcare & WellnessRx Trust (the Fund ), including a majority of the Trustees who have no direct or indirect interest in the Investment Advisory Agreement (the Advisory Agreement ) and are not interested persons of the Fund, as defined in the 1940 Act (the Independent Board Members ), are required to review and approve the terms of the Fund's proposed Advisory Agreement. In this regard, the Board reviewed and approved, during the most recent six month period covered by this report, the Advisory Agreement with Gabelli Funds, LLC (the Adviser ) for the Fund.

More specifically, at a meeting held on February 23, 2016, the Board, including the Independent Board Members, considered the factors and reached the conclusions described below relating to the selection of the Adviser and the approval of the Advisory Agreement.

#### **Nature, Extent, and Quality of Services.**

The Independent Board Members considered information regarding the portfolio managers, the depth of the analyst pool available to the Adviser and the portfolio managers, the scope of administrative, shareholder, and other services supervised or provided by the Adviser and the absence of significant service problems reported to the Board. The Independent Board Members noted the experience, length of service, and reputation of the portfolio managers.

#### **Investment Performance of the Fund and Adviser.**

The Independent Board Members considered one year, three year and five year investment performance for the Fund as compared with relevant sector equity indices and the performance of other sector equity closed-end and open-end funds prepared by Broadridge, including other funds focused on healthcare or life sciences. The Independent Board Members noted that the Fund's NAV performance was below the median of funds in its Broadridge peer group for the prior one, three, and five year periods. The Independent Board Members also recognized that the performance of many of the funds in the Broadridge peer group is not necessarily a good comparison for the Fund because of the Fund's unique investment strategy compared with the investment strategies of many funds in the peer group. The Independent Board Members therefore recognized the more limited usefulness of the Broadridge peer group comparison and concluded that the Adviser was delivering satisfactory performance results consistent with the investment strategy being pursued by the Fund. The Independent Board Members also noted that the net asset value of the Fund had (i) underperformed the S&P 500 Health Care Index over the one year, three year, and five year periods, (ii) outperformed the S&P 500 Consumer Staples Index over the three year and five year periods and underperformed the S&P 500 Consumer Staples Index over the one year period, and (iii) outperformed an index comprised of 50% S&P 500 Health Care Index and 50% S&P 500 Consumer Staples Index over the five year period and underperformed an index comprised of 50% S&P 500 Health Care Index and 50% S&P Consumer Staples Index over the one year and three year periods.

#### **Costs of Services and Profits Realized by the Adviser.**

**(a) Costs of Services to Fund: Fees and Expenses.** The Independent Board Members considered the Fund's advisory fee rate and expense ratio relative to industry averages for the Fund's Broadridge peer group category and the advisory fees charged by the Adviser and its affiliates to other fund and non-fund clients. The Independent Board Members noted that the mix of services under the Agreement is much more extensive than those under the advisory agreements for non-fund clients. The Independent Board Members noted that the investment advisory fee (as a percentage of assets attributable to common shares), advisory fee (as a percentage of total managed assets), other non-advisory

expenses and total expense ratio paid by the Fund are higher than the median and

**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited) (Continued)**

average for its Broadridge peer group. They were advised that the above average other non-advisory expenses and total expense ratio related to the large number of shareholder accounts and related transfer agency costs. They concluded that the advisory fee is acceptable based upon the qualifications, experience, and reputation of the Adviser.

**(b) Profitability and Costs of Services to Adviser.** The Independent Board Members considered the Adviser's overall profitability and costs. The Independent Board Members referred to the Board Materials for the pro forma income statements for the Adviser and the Fund for the period ended December 31, 2015. They noted how the pro forma income statements for the Fund illustrated how the Adviser's profitability would be affected as the Fund asset levels change. The Independent Board Members also considered whether the amount of profit is a fair entrepreneurial profit for the management of the Fund, and noted that the Adviser has substantially increased its resources devoted to Fund matters in response to recently enacted regulatory requirements and new or enhanced Fund policies and procedures. The Independent Board Members concluded that the profitability to the Adviser of managing the Fund was reasonable.

**Extent of Economies of Scale as Fund Grows.**

The Independent Board Members considered whether there have been economies of scale with respect to the management of the Fund and whether the Fund has appropriately benefited from any economies of scale. The Independent Board Members noted that, although the ability of the Fund to realize economies of scale through growth is more limited than for an open-end fund, economies of scale may develop for certain funds as their assets increase and their fund-level expenses decline as a percentage of assets, but that fund-level economies of scale may not necessarily result in Adviser-level economies of scale. The Independent Board Members concluded that there was an appropriate sharing of economies of scale.

**Whether Fee Levels Reflect Economies of Scale.**

The Independent Board Members noted that the advisory fee rate for the period does not take into account any potential sharing of economies of scale through breakpoints.

**Other Relevant Considerations.**

**(a) Adviser Personnel and Methods.** The Independent Board Members considered the size, education, and experience of the Adviser's staff, the Adviser's fundamental research capabilities and the Adviser's approach to recruiting, training, and retaining portfolio managers and other research and management personnel, and concluded that in each of these areas the Adviser was structured in such a way to support the high level of services being provided to the Fund.

**(b) Other Benefits to the Adviser.** The Independent Board Members also considered the character and amount of other incidental benefits received by the Adviser and its affiliates from its association with the Fund. The Independent Board Members considered the brokerage commissions paid to an affiliate of the Adviser. The Independent Board Members concluded that potential "fall-out" benefits that the Adviser and its affiliates may receive, such as brokerage commissions paid to an affiliated broker, greater name recognition, or increased ability to obtain research services, appear to be reasonable, and may in some cases benefit the Fund.



**The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust**

**Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited) (Continued)**

**Conclusions**

In considering the Advisory Agreement, the Independent Board Members did not identify any factor as all important or all controlling, and instead considered these factors collectively in light of the Fund's surrounding circumstances. The Independent Board Members concluded that the Fund enjoyed highly experienced portfolio management services and good ancillary services. They were aware that the NAV performance record had been below the median during the one, three, and five year reporting periods ended December 31, 2015 in comparison with peers but recognized that many of the peers were not good comparisons for the Fund because of its unique investment strategy. In addition, the Fund had performed satisfactorily in relation to a consumer staples index and a blended healthcare and consumer staples index, but had underperformed a healthcare index over the one, three, and five year periods. As a part of its decision making process the Independent Board Members considered, generally, that shareholders invested in the Fund knowing that the Adviser managed the Fund and knowing its investment advisory fee schedule. As such, the Independent Board Members considered, in particular, whether the Adviser managed the Fund in accordance with its investment objectives and policies as disclosed to shareholders. In addition, the Independent Board Members believe that a long term relationship with a capable, conscientious adviser is in the best interests of the Fund. The Independent Board Members concluded that the Fund was managed by the Adviser consistent with its investment objectives and policies. On the basis of the foregoing and without assigning particular weight to any single conclusion, the Independent Board Members determined to recommend continuation of the Advisory Agreement to the full Board.

Based on a consideration of all these factors in their totality, the Board Members, including all of the Independent Board Members, determined that the Fund's advisory fee was fair and reasonable with respect to the quality of services provided and in light of the other factors described above that the Board deemed relevant. Accordingly, the Board Members determined to approve the continuation of the Fund's Advisory Agreement. The Board Members based their decision on evaluations of all these factors as a whole and did not consider any one factor as all important or controlling.

**AUTOMATIC DIVIDEND REINVESTMENT  
AND VOLUNTARY CASH PURCHASE PLANS**

**Enrollment in the Plan**

It is the policy of The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust to automatically reinvest dividends payable to common shareholders. As a registered shareholder, you automatically become a participant in the Fund's Automatic Dividend Reinvestment Plan (the Plan). The Plan authorizes the Fund to credit shares of common stock to participants upon an income dividend or a capital gains distribution regardless of whether the shares are trading at a discount or a premium to net asset value. All distributions to shareholders whose shares are registered in their own names will be automatically reinvested pursuant to the Plan in additional shares of the Fund. Plan participants may send their stock certificates to Computershare Trust Company, N.A. (Computershare) to be held in their dividend reinvestment account. Registered shareholders wishing to receive their distribution in cash must submit this request in writing to:

The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust

c/o Computershare

P.O. Box 30170

College Station, TX 77842-3170

Shareholders requesting this cash election must include the shareholder's name and address as they appear on the share certificate. Shareholders with additional questions regarding the Plan or requesting a copy of the terms of the Plan may contact Computershare at (800) 336-6983.

If your shares are held in the name of a broker, bank, or nominee, you should contact such institution. If such institution is not participating in the Plan, your account will be credited with a cash dividend. In order to participate in the Plan through such institution, it may be necessary for you to have your shares taken out of street name and re-registered in your own name. Once registered in your own name, your dividends will be automatically reinvested. Certain brokers participate in the Plan. Shareholders holding shares in street name at participating institutions will have dividends automatically reinvested. Shareholders wishing a cash dividend at such institution must contact their broker to make this change.

The number of shares of common stock distributed to participants in the Plan in lieu of cash dividends is determined in the following manner. Under the Plan, whenever the market price of the Fund's common stock is equal to or exceeds net asset value at the time shares are valued for purposes of determining the number of shares equivalent to the cash dividends or capital gains distribution, participants are issued shares of common stock valued at the greater of (i) the net asset value as most recently determined or (ii) 95% of the then current market price of the Fund's common stock. The valuation date is the dividend or distribution payment date or, if that date is not a New York Stock Exchange (NYSE) trading day, the next trading day. If the net asset value of the common stock at the time of valuation exceeds the market price of the common stock, participants will receive shares from the Fund valued at market price. If the Fund should declare a dividend or capital gains distribution payable only in cash, Computershare will buy common stock in the open market, or on the NYSE or elsewhere, for the participants' accounts, except that Computershare will endeavor to terminate purchases in the open market and cause the Fund to issue shares at net asset value if, following the commencement of such purchases, the market value of the common stock exceeds the then current net asset value.

The automatic reinvestment of dividends and capital gains distributions will not relieve participants of any income tax which may be payable on such distributions. A participant in the Plan will be treated for federal income tax purposes

as having received, on a dividend payment date, a dividend or distribution in an amount equal to the cash the participant could have received instead of shares.

### **Voluntary Cash Purchase Plan**

The Voluntary Cash Purchase Plan is yet another vehicle for our shareholders to increase their investment in the Fund. In order to participate in the Voluntary Cash Purchase Plan, shareholders must have their shares registered in their own name.

Participants in the Voluntary Cash Purchase Plan have the option of making additional cash payments to Computershare for investments in the Fund's shares at the then current market price. Shareholders may send an amount from \$250 to \$10,000. Computershare will use these funds to purchase shares in the open market on or about the 1st and 15th of each month. Computershare will charge each shareholder who participates \$0.75, plus a pro rata share of the brokerage commissions. Brokerage charges for such purchases are expected to be less than the usual brokerage charge for such transactions. It is suggested that any voluntary cash payments be sent to Computershare, P.O. Box 30170, College Station, TX 77842-3170 such that Computershare receives such payments approximately 10 days before the 1st and 15th of the month. Funds not received at least five days before the investment date shall be held for investment until the next purchase date. A payment may be withdrawn without charge if notice is received by Computershare at least 48 hours before such payment is to be invested.

Shareholders wishing to liquidate shares held at Computershare must do so in writing or by telephone. Please submit your request to the above mentioned address or telephone number. Include in your request your name, address, and account number. The cost to liquidate shares is \$2.50 per transaction as well as the brokerage commission incurred. Brokerage charges are expected to be less than the usual brokerage charge for such transactions.

For more information regarding the Dividend Reinvestment Plan and Voluntary Cash Purchase Plan, brochures are available by calling (914) 921-5070 or by writing directly to the Fund.

The Fund reserves the right to amend or terminate the Plan as applied to any voluntary cash payments made and any dividend or distribution paid subsequent to written notice of the change sent to the members of the Plan at least 90 days before the record date for such dividend or distribution. The Plan also may be amended or terminated by Computershare on at least 90 days written notice to participants in the Plan.

## **THE GABELLI HEALTHCARE & WELLNESS<sup>Rx</sup> TRUST**

### **AND YOUR PERSONAL PRIVACY**

#### **Who are we?**

The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust is a closed-end management investment company registered with the Securities and Exchange Commission under the Investment Company Act of 1940. We are managed by Gabelli Funds, LLC, which is affiliated with GAMCO Investors, Inc. GAMCO Investors, Inc. is a publicly held company that has subsidiaries that provide investment advisory services for a variety of clients.

#### **What kind of non-public information do we collect about you if you become a Fund shareholder?**

When you purchase shares of the Fund on the New York Stock Exchange, you have the option of registering directly with our transfer agent in order, for example, to participate in our dividend reinvestment plan.

*Information you give us on your application form.* This could include your name, address, telephone number, social security number, bank account number, and other information.

*Information about your transactions with us.* This would include information about the shares that you buy or sell; it may also include information about whether you sell or exercise rights that we have issued from time to time. If we hire someone else to provide services like a transfer agent we will also have information about the transactions that you conduct through them.

#### **What information do we disclose and to whom do we disclose it?**

We do not disclose any non-public personal information about our customers or former customers to anyone other than our affiliates, our service providers who need to know such information, and as otherwise permitted by law. If you want to find out what the law permits, you can read the privacy rules adopted by the Securities and Exchange Commission. They are in volume 17 of the Code of Federal Regulations, Part 248. The Commission often posts information about its regulations on its website, [www.sec.gov](http://www.sec.gov).

#### **What do we do to protect your personal information?**

We restrict access to non-public personal information about you to the people who need to know that information in order to provide services to you or the Fund and to ensure that we are complying with the laws governing the securities business. We maintain physical, electronic, and procedural safeguards to keep your personal information confidential.

This page was intentionally left blank.

**THE GABELLI HEALTHCARE & WELLNESS<sup>Rx</sup> TRUST**

**One Corporate Center**

**Rye, NY 10580-1422**

**Portfolio Management Team Biographies**

**Mario J. Gabelli, CFA**, is Chairman, Chief Executive Officer, and Chief Investment Officer - Value Portfolios of GAMCO Investors, Inc. that he founded in 1977, and Chief Investment Officer - Value Portfolios of Gabelli Funds, LLC and GAMCO Asset Management Inc. He is also Chief Executive Officer and Chairman of the Board of Directors of Associated Capital Group, Inc. Mr. Gabelli is a summa cum laude graduate of Fordham University and holds an MBA degree from Columbia Business School and Honorary Doctorates from Fordham University and Roger Williams University.

**Kevin V. Dreyer** joined Gabelli in 2005 as a research analyst covering companies within the consumer sector. Currently he is a Managing Director and Co-Chief Investment Officer for GAMCO Investors, Inc.'s Value team. In addition, he serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Dreyer received a BSE from the University of Pennsylvania and an MBA from Columbia Business School.

**Jeffrey J. Jonas, CFA**, joined Gabelli in 2003 as a research analyst. He focuses on companies in the cardiovascular, healthcare services, and pharmacy benefits management sectors, among others. He also serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Jonas was a Presidential Scholar at Boston College, where he received a BS in Finance and Management Information Systems.

**Certifications**

The Fund's Chief Executive Officer has certified to the New York Stock Exchange ( NYSE ) that, as of June 8, 2016, she was not aware of any violation by the Fund of applicable NYSE corporate governance listing standards. The Fund reports to the SEC on Form N-CSR which contains certifications by the Fund's principal executive officer and principal financial officer that relate to the Fund's disclosure in such reports and that are required by Rule 30a-2(a) under the 1940 Act.

We have separated the portfolio managers' commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers' commentary is unrestricted. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at [www.gabelli.com](http://www.gabelli.com).

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading "Specialized Equity Funds," in Monday's The Wall Street Journal. It is also listed in Barron's Mutual Funds/Closed End Funds section under the heading "Specialized Equity Funds."

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting [www.gabelli.com](http://www.gabelli.com).

The NASDAQ symbol for the Net Asset Value is XXGRX.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may from time to time purchase its common shares in the open market when the Fund's shares are trading at a discount of 10% or more from the net asset value of the shares. The Fund may also, from time to time, purchase its preferred shares in the open market when the preferred shares are trading at a discount to the liquidation value.

THE GABELLI HEALTHCARE & WELLNESS<sup>RX</sup> TRUST

One Corporate Center

Rye, NY 10580-1422

t 800-GABELLI (800-422-3554)

f 914-921-5118

e info@gabelli.com

GABELLI.COM

TRUSTEES

Mario J. Gabelli, CFA  
Chairman &  
Chief Executive Officer,  
GAMCO Investors, Inc.  
Chairman and  
Chief Executive Officer,  
Associated Capital Group, Inc.

Anthony J. Colavita  
President,  
Anthony J. Colavita, P.C.

James P. Conn  
Former Managing Director &  
Chief Investment Officer,  
Financial Security Assurance  
Holdings Ltd.

Vincent D. Enright  
Former Senior Vice President &  
Chief Financial Officer,  
KeySpan Corp.

Jeffrey J. Jonas, CFA  
Portfolio Manager,  
Gabelli Funds, LLC

Robert C. Kolodny, MD

OFFICERS

Agnes Mullady  
President

Joseph H. Egan  
Treasurer

Andrea R. Mango  
Secretary & Vice President

Richard J. Walz  
Chief Compliance Officer

Carter W. Austin  
Vice President

Wayne C. Pinsent, CFA  
Vice President & Ombudsman

David I. Schachter  
Vice President

Adam E. Tokar  
Vice President

INVESTMENT ADVISER

Gabelli Funds, LLC  
One Corporate Center

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

Physician,  
Principal of KBS  
Management LLC

Rye, New York 10580-1422

**CUSTODIAN**

Kuni Nakamura  
President,  
Advanced Polymer, Inc.

The Bank of New York Mellon

**COUNSEL**

Anthonie C. van Ekris  
Chairman,  
BALMAC International, Inc.

Willkie Farr & Gallagher LLP

**TRANSFER AGENT AND  
REGISTRAR**

Salvatore J. Zizza  
Chairman,  
Zizza & Associates Corp.

Computershare Trust Company, N.A.

**GRX Q2/2016**

**Item 2. Code of Ethics.**

Not applicable.

**Item 3. Audit Committee Financial Expert.**

Not applicable.

**Item 4. Principal Accountant Fees and Services.**

Not applicable.

**Item 5. Audit Committee of Listed Registrants.**

Not applicable.

**Item 6. Investments.**

(a) Schedule of Investments in securities of unaffiliated issuers as of the close of the reporting period is included as part of the report to shareholders filed under Item 1 of this form.

(b) Not applicable.

**Item 7. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.**

Not applicable.

**Item 8. Portfolio Managers of Closed-End Management Investment Companies.**

There has been no change, as of the date of this filing, in any of the portfolio managers identified in response to paragraph (a)(1) of this Item in the registrant's most recently filed annual report on Form N-CSR.

**Item 9. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.**

**REGISTRANT PURCHASES OF EQUITY SECURITIES**

| Period                             | (a) Total Number of<br>Shares (or Units)<br>Purchased | (b) Average Price Paid<br>per Share (or Unit) | (c) Total Number of<br>Shares (or Units)<br>Purchased as Part of<br>Publicly Announced<br>Plans or Programs | (d) Maximum Number (or<br>Approximate Dollar Value) of<br>Shares (or Units) that May Yet Be<br>Purchased Under the Plans or<br>Programs |           |
|------------------------------------|-------------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------|
|                                    |                                                       |                                               |                                                                                                             |                                                                                                                                         |           |
| Month                              | Common - N/A                                          | Common - N/A                                  | Common - N/A                                                                                                | Common - 19,848,104                                                                                                                     |           |
| #1 01/01/16<br>through<br>01/31/16 | Preferred Series A - N/A                              | Preferred Series A - N/A                      | Preferred Series A - N/A                                                                                    | Preferred Series A                                                                                                                      | 1,200,000 |
|                                    | Preferred Series B - N/A                              | Preferred Series B - N/A                      | Preferred Series B - N/A                                                                                    | Preferred Series B                                                                                                                      | 1,400,000 |
| Month                              | Common - N/A                                          | Common - N/A                                  | Common - N/A                                                                                                | Common - 19,848,104                                                                                                                     |           |
| #2 02/01/16<br>through<br>02/29/16 | Preferred Series A - N/A                              | Preferred Series A - N/A                      | Preferred Series A - N/A                                                                                    | Preferred Series A                                                                                                                      | 1,200,000 |
|                                    | Preferred Series B - N/A                              | Preferred Series B - N/A                      | Preferred Series B - N/A                                                                                    | Preferred Series B                                                                                                                      | 1,400,000 |
| Month                              | Common - N/A                                          | Common - N/A                                  | Common - N/A                                                                                                | Common - 19,848,104                                                                                                                     |           |
| #3 03/01/16<br>through<br>03/31/16 | Preferred Series A - N/A                              | Preferred Series A - N/A                      | Preferred Series A - N/A                                                                                    | Preferred Series A                                                                                                                      | 1,200,000 |
|                                    | Preferred Series B - N/A                              | Preferred Series B - N/A                      | Preferred Series B - N/A                                                                                    | Preferred Series B                                                                                                                      | 1,400,000 |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

|                                    |                          |                          |                          |                              |
|------------------------------------|--------------------------|--------------------------|--------------------------|------------------------------|
| Month                              | Common - N/A             | Common - N/A             | Common - N/A             | Common - 19,848,104          |
| #4 04/01/16<br>through<br>04/30/16 | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A 1,200,000 |
|                                    | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B 1,400,000 |
| Month                              | Common - N/A             | Common - N/A             | Common - N/A             | Common - 19,848,104          |
| #5 05/01/16<br>through<br>05/31/16 | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A 1,200,000 |
|                                    | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B 1,400,000 |
| Month                              | Common - N/A             | Common - N/A             | Common - N/A             | Common - 19,848,104          |
| #6 06/01/16<br>through<br>06/30/16 | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A 1,200,000 |
|                                    | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B 1,413,272 |
| Total                              | Common - N/A             | Common - N/A             | Common - N/A             | N/A                          |

|                          |                          |                             |
|--------------------------|--------------------------|-----------------------------|
| Preferred Series A - N/A | Preferred Series A - N/A | Preferred Series A -<br>N/A |
| Preferred Series B - N/A | Preferred Series B - N/A | Preferred Series B -<br>N/A |

Footnote columns (c) and (d) of the table, by disclosing the following information in the aggregate for all plans or programs publicly announced:

- a. The date each plan or program was announced The notice of the potential repurchase of common and preferred shares occurs quarterly in the Fund's quarterly report in accordance with Section 23(c) of the Investment Company Act of 1940, as amended.
- b. The dollar amount (or share or unit amount) approved Any or all common shares outstanding may be repurchased when the Fund's common shares are trading at a discount of 10% or more from the net asset value of the shares.  
Any or all preferred shares outstanding may be repurchased when the Fund's preferred shares are trading at a discount to the liquidation value of \$25.00.
- c. The expiration date (if any) of each plan or program The Fund's repurchase plans are ongoing.
- d. Each plan or program that has expired during the period covered by the table The Fund's repurchase plans are ongoing.
- e. Each plan or program the registrant has determined to terminate prior to expiration, or under which the registrant does not intend to make further purchases. The Fund's repurchase plans are ongoing.

**Item 10. Submission of Matters to a Vote of Security Holders.**

There have been no material changes to the procedures by which the shareholders may recommend nominees to the registrant's Board of Trustees, where those changes were implemented after the registrant last provided disclosure in response to the requirements of Item 407(c)(2)(iv) of Regulation S-K (17 CFR 229.407) (as required by Item 22(b)(15) of Schedule 14A (17 CFR 240.14a-101)), or this Item.

**Item 11. Controls and Procedures.**

- (a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).

(b)

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-CSRS

There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d))) that occurred during the registrant's second fiscal quarter of the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 12. Exhibits.**

- (a)(1) Not applicable.
- (a)(2) Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.
- (a)(3) Not applicable.
- (b) Certifications pursuant to Rule 30a-2(b) under the 1940 Act and Section 906 of the Sarbanes- Oxley Act of 2002 are attached hereto.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) The Gabelli Healthcare & Wellness<sup>Rx</sup> Trust

By (Signature and Title)\* /s/ Agnes Mullady  
Agnes Mullady, Principal Executive Officer

Date 9/01/2016

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)\* /s/ Agnes Mullady  
Agnes Mullady, Principal Executive Officer

Date 9/01/2016

By (Signature and Title)\* /s/ Joseph Egan  
Joseph Egan, Principal Financial Officer

Date 9/01/2016

\* Print the name and title of each signing officer under his or her signature.